A Phase 1/2 Study of ISIS 481464, an Antisense Oligonucleotide Inhibitor of STAT3, Administered to Patients With Advanced Cancers

Inclusion Criteria:

- Aged 18 years or older

- Tumors that are relapsed or refractory to at least 1 prior anti-cancer systemic
therapy and for which no standard therapy exists

- Expansion cohort only: Advanced lymphoma confirmed by histopathology

- Measurable or evaluable disease according to RECIST for solid tumors or according to
IWRC for NHL tumors

- ECOG Performance Status less than or equal to 2

- Life expectancy greater than 12 weeks in the opinion of the Investigator

Exclusion Criteria:

- Any active or uncontrolled infection

- NYHA Grade II or greater congestive heart failure

- History of myocardial infarction within 6 months prior to screening

- Prior radiation therapy, chemotherapy, hormonal therapy, or immunotherapy within 4
weeks prior to screening or 5 half-lives of the therapy, whichever is shorter